IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer
Wang, Zhi-jie1,2; An, Tong-tong1; Mok, Tony4; Yang, Lu1; Bai, Hua1,2; Zhao, Jun1,2; Duan, Jian-chun1,2; Wu, Mei-na1,2; Wang, Yu-yan1,2; Li, Ping-ping1,3; Sun, Hong3; Yang, Ping5; Wang, Jie1,2
关键词Egfr Tyrosine Kinase Inhibitor Maintenance Therapy Non-small-cell Lung Cancer
刊名CHINESE JOURNAL OF CANCER RESEARCH
2011-06-01
DOI10.1007/s11670-011-0112-5
23期:2页:112-117
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者China National Funds for Distinguished Young Scientists ; Capital Development Foundation ; China National Funds for Distinguished Young Scientists ; Capital Development Foundation
研究领域[WOS]Oncology
关键词[WOS]PHASE-III TRIAL ; FACTOR RECEPTOR MUTATIONS ; GEFITINIB ; GEMCITABINE ; ERLOTINIB ; BEVACIZUMAB ; CARBOPLATIN ; CISPLATIN ; PLACEBO ; TUMORS
英文摘要

To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group).

The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC).

PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively (hazard ratio [HR], 0.99; 95% Confidence Interval [CI]: 0.69-1.42; P=0.947). In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group (HR, 0.48; 95% CI: 0.27-0.85; P=0.012). In patients with wild type EGFR, the risk for disease progression was comparable between the two groups (HR, 1.23; 95% CI: 0.61-2.51; P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI: 0.27 to 1.06; P=0.072). There was also no difference in the incidence of adverse events between the two groups.

EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed.

语种英语
所属项目编号81025012 ; 30772472
资助者China National Funds for Distinguished Young Scientists ; Capital Development Foundation ; China National Funds for Distinguished Young Scientists ; Capital Development Foundation
WOS记录号WOS:000290804600005
Citation statistics
Cited Times:2[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52025
Collection北京大学临床肿瘤学院
作者单位1.Gen Hosp Navy, Dept Oncol, Beijing, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing 100871, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Integrat Med, Beijing 100871, Peoples R China
5.Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
Recommended Citation
GB/T 7714
Wang, Zhi-jie,An, Tong-tong,Mok, Tony,et al. Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(2):112-117.
APA Wang, Zhi-jie.,An, Tong-tong.,Mok, Tony.,Yang, Lu.,Bai, Hua.,...&Wang, Jie.(2011).Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer.CHINESE JOURNAL OF CANCER RESEARCH,23(2),112-117.
MLA Wang, Zhi-jie,et al."Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer".CHINESE JOURNAL OF CANCER RESEARCH 23.2(2011):112-117.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
[Mok, Tony]'s Articles
百度学术
百度学术Similar articles in
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
[Mok, Tony]'s Articles
必应学术
必应学术Similar articles in
[Wang, Zhi-jie]'s Articles
[An, Tong-tong]'s Articles
[Mok, Tony]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.